Tsilimparis Nikolaos, Law Yuk, Rohlffs Fiona, Spanos Konstantinos, Debus Eike Sebastian, Kölbel Tilo
Department of Vascular Medicine, German Aortic Center, University Heart Center, Hamburg, Germany; Department of Vascular Surgery, Hospital of Ludwig-Maximilians University LMU, Munich, Germany.
Department of Vascular Medicine, German Aortic Center, University Heart Center, Hamburg, Germany.
J Vasc Surg. 2020 May;71(5):1464-1471. doi: 10.1016/j.jvs.2019.06.205. Epub 2020 Feb 13.
Extension of aortic disease to the aortic arch is common, frequently requiring cervical debranching procedures to maintain patency of supra-aortic branches. Endovascular aortic arch repair is an attractive alternative in the treatment of aortic arch disease for high-risk patients with thoracoabdominal diseases encroaching on the arch. The aim of our study was to report our experience of fenestrated endovascular repair in the aortic arch.
A retrospective review of prospectively collected data involving consecutive patients in a single tertiary center treated with custom-made fenestrated endografts for the aortic arch (Cook Medical, Bloomington, Ind) was undertaken. End points included technical success, perioperative mortality and morbidity, reintervention, and late survival.
Between 2011 and 2017, there were 44 patients with a mean age of 67 ± 9 years (27 male [61%]) who were treated with fenestrated endografts for arch aneurysm (n = 11 [25%]), arch penetrating aortic ulcer (n = 6 [14%]), thoracoabdominal aneurysm with arch involvement (n = 11 [25%]), postdissection false lumen aneurysm (n = 13 [29%]), or lusorian artery aneurysm (n = 3 [7%]). The proximal landing zone was at Ishimaru zone 0 in 12 cases (27%), zone 1 in 27 cases (62%), and zone 2 in 5 cases (11%). Nine patients (20%) underwent a unilateral carotid-subclavian bypass, two (5%) a bilateral carotid-subclavian bypass, and four (9%) a subclavian transposition. In total, of the 73 target supra-aortic vessels (average of 1.7 target vessels per patient), 37 were treated with fenestrations and 36 with scallops. The mean operation time, fluoroscopy time, and contrast material volume were 215 ± 152 minutes, 33 ± 23 minutes, and 114 ± 45 mL, respectively. Technical success was 95% (42/44). The median intensive care unit and hospital stays were 3 ± 1 days and 7 ± 6 days, respectively. The 30-day mortality was 9% (4/44; one graft displacement and stroke, one retrograde type A dissection, one access complication and stroke, and one death of unknown cause). Major stroke occurred in three (7%), minor stroke in one (2%), temporary spinal cord ischemia in three (7%), and renal injury in three (7%) patients, whereas three (7%) patients required early reintervention. With mean follow-up of 18 ± 17 months, 10 more patients required secondary interventions, most of which (90%) were planned distal intervention to complete the repair of thoracoabdominal diseases. Overall survival rates were 78% ± 7% and 72% ± 8% at postoperative years 1 and 2, respectively.
Fenestrated endograft repair of aortic arch disease is a feasible technique with a high technical success rate and acceptable rates of stroke and paraplegia. A high number of secondary interventions were needed to complete the treatment of underlying diseases.
主动脉疾病扩展至主动脉弓很常见,常需行颈部去分支手术以维持主动脉弓上分支的通畅。对于合并胸腹部疾病侵犯主动脉弓的高危患者,血管腔内主动脉弓修复术是治疗主动脉弓疾病的一种有吸引力的替代方法。本研究的目的是报告我们在主动脉弓开窗血管腔内修复方面的经验。
对前瞻性收集的数据进行回顾性分析,这些数据来自于一家单一的三级中心连续接受定制开窗腔内移植物(库克医疗公司,印第安纳州布卢明顿)治疗主动脉弓的患者。终点指标包括技术成功率、围手术期死亡率和发病率、再次干预以及远期生存率。
2011年至2017年间,44例患者平均年龄为67±9岁(男性27例[61%]),接受开窗腔内移植物治疗主动脉弓瘤(n = 11例[25%])、主动脉弓穿透性溃疡(n = 6例[14%])、累及主动脉弓的胸腹主动脉瘤(n = 11例[25%])、夹层后假腔动脉瘤(n = 13例[29%])或迷走动脉动脉瘤(n = 3例[7%])。近端锚定区位于石丸0区12例(27%),1区27例(62%),2区5例(11%)。9例患者(20%)接受了单侧颈动脉-锁骨下动脉旁路移植术,2例(5%)接受了双侧颈动脉-锁骨下动脉旁路移植术,4例(9%)接受了锁骨下动脉转位术。总共73支主动脉弓上目标血管(平均每位患者1.7支目标血管),37支通过开窗治疗,36支通过扇贝形开窗治疗。平均手术时间、透视时间和造影剂用量分别为215±152分钟、33±23分钟和114±45毫升。技术成功率为95%(42/44)。重症监护病房和住院时间的中位数分别为3±1天和7±6天。30天死亡率为9%(4/44;1例移植物移位和卒中,1例逆行A型夹层,1例入路并发症和卒中,1例不明原因死亡)。3例(7%)发生严重卒中,1例(2%)发生轻度卒中,3例(7%)发生短暂性脊髓缺血,3例(7%)发生肾损伤,3例(7%)患者需要早期再次干预。平均随访18±17个月,又有10例患者需要二次干预,其中大部分(90%)是计划性远端干预以完成胸腹部疾病的修复。术后1年和2年的总体生存率分别为78%±7%和72%±8%。
开窗腔内移植物修复主动脉弓疾病是一种可行的技术,技术成功率高,卒中及截瘫发生率可接受。需要大量的二次干预来完成对基础疾病的治疗。